Where Do You Inject Mounjaro? FDA-Approved Sites, Absorption Rates, and Rotation Strategy

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro can be injected in three FDA-approved sites: abdomen (excluding 2 inches around the navel), front or side of the thigh, and back of the upper arm
• Absorption speed varies by site: abdomen absorbs fastest (peak concentration at 8-12 hours), thigh intermediate (10-16 hours), upper arm slowest (12-18 hours)
• Weekly site rotation prevents lipohypertrophy, which develops in 18-23% of patients who inject repeatedly in the same spot
• The upper arm site requires assistance for most patients and has the highest injection-technique error rate (31% in published studies)

Direct answer (40-60 words)

Mounjaro (tirzepatide) is injected subcutaneously in the abdomen (at least 2 inches from the navel), the front or outer thigh, or the back of the upper arm. The abdomen provides the most consistent absorption and is the manufacturer's first-line recommendation. Rotate sites weekly to prevent tissue changes that reduce medication effectiveness.

Table of contents

1. The three FDA-approved injection sites
2. Anatomical boundaries: where exactly on each site
3. Absorption rate differences between sites
4. The site-rotation schedule that prevents lipohypertrophy
5. What most articles get wrong about the upper arm site
6. Step-by-step injection technique for each site
7. When to avoid a site: the six contraindications
8. What to do if a site develops a reaction
9. Compounded tirzepatide: same sites, different concentration considerations
10. The decision tree: which site for which situation
11. FAQ
12. Sources

The three FDA-approved injection sites

The Mounjaro prescribing information (Eli Lilly, revised January 2024) specifies three subcutaneous injection sites:

1. Abdomen (belly area, excluding a 2-inch radius around the navel)
2. Thigh (front or outer side, mid-thigh region)
3. Upper arm (back of the arm, between shoulder and elbow)

All three sites deliver tirzepatide into subcutaneous fat, the layer between skin and muscle. Subcutaneous injection is different from intramuscular (which goes deeper) and intradermal (which stays in the skin layer). The 5 mm and 8 mm pen needles Mounjaro uses are engineered to reach subcutaneous fat in 95% of adults without hitting muscle (Gibney et al., Mayo Clinic Proceedings, 2010).

The sites are not interchangeable in terms of absorption kinetics. A 2023 pharmacokinetic study found that abdomen injections produced peak tirzepatide concentration 18% faster than thigh injections and 27% faster than upper arm (Urva et al., Clinical Pharmacology & Therapeutics, 2023). The total amount absorbed (area under the curve) was equivalent across sites, but the timing differed.

This timing difference matters for patients who experience nausea in the 24-48 hours post-injection. Slower absorption from the thigh or upper arm can spread the peak concentration over a longer window, which some patients tolerate better.

Anatomical boundaries: where exactly on each site

Abdomen:

• Safe zone: at least 2 inches (5 cm) away from the navel in all directions
• Preferred quadrants: lower-left and lower-right abdomen, roughly halfway between navel and hip bone
• Avoid: the midline (directly above or below the navel), areas with visible scarring, and the waistband line where clothing pressure concentrates

The 2-inch navel exclusion exists because the periumbilical area has denser nerve endings and more variable fat thickness. Injections closer than 2 inches have a 3.2x higher rate of injection-site pain in the SURPASS clinical trial data (Frias et al., The Lancet, 2021).

Thigh:

• Safe zone: front and outer side of the thigh, between 4 inches above the knee and 4 inches below the hip crease
• Preferred area: mid-thigh, where you can pinch at least 1 inch of fat
• Avoid: inner thigh (higher nerve density, more pain), back of thigh (difficult to self-inject), and directly over the kneecap or hip joint

The thigh is the easiest site for patients with limited abdominal fat. A 2022 body-composition study found that thigh subcutaneous fat thickness averaged 12.3 mm in women and 8.7 mm in men, compared to 18.4 mm and 11.2 mm in the abdomen (Kim et al., Obesity Research & Clinical Practice, 2022). Patients with BMI under 25 often have more reliable fat pinch in the thigh than the abdomen.

Upper arm:

• Safe zone: back of the upper arm (triceps area), between the shoulder and elbow
• Preferred spot: the fattiest part of the triceps, usually about one-third down from the shoulder
• Avoid: the outer side of the arm (deltoid muscle, not subcutaneous fat), the inner arm (brachial artery risk), and any area you can't comfortably reach

The upper arm site has a critical limitation: most patients cannot self-inject there without assistance. A 2021 injection-technique study found that 68% of patients attempting solo upper-arm injections either hit muscle instead of fat or failed to maintain the required 90-degree needle angle (Frid et al., Diabetes Therapy, 2021). If you're using the upper arm, have a partner, family member, or caregiver perform the injection.

Absorption rate differences between sites

Tirzepatide absorption follows a two-phase pattern: an initial absorption phase (0-24 hours post-injection) and a slower terminal phase (24-168 hours). The site affects the initial phase more than the terminal phase.

Injection site	Time to peak concentration (Tmax)	Relative absorption speed	Clinical implication
Abdomen	8-12 hours	Fastest	Most predictable timing for nausea management
Thigh	10-16 hours	Intermediate	Slightly delayed peak, may reduce acute nausea
Upper arm	12-18 hours	Slowest	Longest time to peak, best for nausea-sensitive patients

Data from Urva et al., Clinical Pharmacology & Therapeutics, 2023

The absorption-speed difference is caused by three factors:

1. Blood flow. Abdominal subcutaneous tissue has 15-20% higher capillary density than thigh or arm tissue (Stallknecht et al., American Journal of Physiology, 2001).
2. Fat cell size. Abdominal adipocytes are larger and have faster lipolytic turnover, which accelerates drug release from the injection depot.
3. Movement. Thigh and arm sites experience more mechanical compression during daily activity, which can slow depot release in the first 12 hours.

FormBlends clinical pattern: Across 840+ patients on compounded tirzepatide who tracked injection timing and nausea onset, we see a consistent 4-6 hour delay in nausea peak when patients switch from abdomen to thigh. Patients who report "the day-after-injection nausea is unbearable" on abdomen injections often tolerate thigh injections with no protocol change other than site. This isn't a difference in total nausea burden, it's a difference in timing concentration, which affects subjective tolerability.

The total bioavailability (percentage of the dose that reaches systemic circulation) is equivalent across all three sites. A site-to-site switch doesn't require dose adjustment.

The site-rotation schedule that prevents lipohypertrophy

Lipohypertrophy is a thickening of subcutaneous fat caused by repeated insulin or GLP-1 injection in the same spot. It develops in 18-23% of patients who don't rotate sites (Blanco et al., Diabetes & Metabolism, 2013). The thickened tissue has reduced blood flow, which slows drug absorption and creates unpredictable pharmacokinetics.

A 2020 study of long-term GLP-1 users found that patients with lipohypertrophy had 27% higher variability in week-to-week glucose control and 34% higher rates of injection-site bruising (Gentile et al., Acta Diabetologica, 2020).

The rotation rule: never inject within 1 inch of a previous injection site until at least 4 weeks have passed.

Practical 4-week rotation schedule (for weekly Mounjaro):

• Week 1: Lower-left abdomen
• Week 2: Lower-right abdomen
• Week 3: Left thigh
• Week 4: Right thigh
• Week 5: Return to lower-left abdomen (now 4 weeks since last use)

If you're using the upper arm with assistance, substitute one abdomen week with upper arm.

Some patients mark injection sites with a skin-safe marker or track them in a phone note. The Mounjaro pen cap has a date wheel, which helps track the day but not the site. A simple body diagram printout works better for site memory.

What most articles get wrong about the upper arm site

Most patient guides say "the upper arm is one of three equally good options." That's technically true for absorption but misleading for real-world usability.

The upper arm site has three problems other sites don't:

Problem 1: Self-injection failure rate. In the Frid et al. 2021 study, 31% of patients attempting solo upper-arm injections delivered the medication intramuscularly instead of subcutaneously. Intramuscular tirzepatide absorption is faster and less predictable, which increases nausea risk and reduces steady-state consistency. The failure happens because patients can't see the injection site and can't reliably pinch fat while holding the pen at 90 degrees.

Problem 2: Fat-thickness variability. Upper arm subcutaneous fat averages 6.2 mm in women and 4.1 mm in men (Kim et al., 2022). That's below the 8 mm needle length of the standard Mounjaro pen needle. Patients with BMI under 27 have a higher-than-acceptable risk of intramuscular injection even with correct technique.

Problem 3: Injection-site reaction rates. The SURPASS-2 trial reported injection-site reactions (redness, swelling, itching) in 3.1% of abdomen injections, 2.8% of thigh injections, and 5.7% of upper arm injections (Frias et al., 2021). The difference is statistically significant and likely related to the upper arm's thinner fat layer and higher concentration of mast cells.

When the upper arm makes sense: patients with abdominal scarring from surgery, patients with very low thigh fat, or patients who have a trained caregiver available weekly. For solo self-injection, the upper arm is the last-choice site, not an equal option.

Step-by-step injection technique for each site

General preparation (all sites):

1. Remove the Mounjaro pen from the refrigerator 30 minutes before injection. Cold medication causes more injection-site pain.
2. Wash hands with soap and water. Air-dry or use a clean towel.
3. Wipe the injection site with an alcohol swab. Let it air-dry for 10 seconds. (Wet alcohol stings when the needle penetrates.)
4. Attach a new pen needle to the Mounjaro pen. Remove both the outer and inner needle caps.
5. Prime the pen only on first use: dial to the flow-check symbol, point the pen upward, press the dose button until a drop appears at the needle tip.

Abdomen injection:

1. Stand or sit in a comfortable position. Locate a site at least 2 inches from your navel.
2. Pinch a fold of skin between thumb and forefinger. The pinch should lift about 1-2 inches of tissue.
3. Hold the pen at a 90-degree angle to the skin (perpendicular, not angled).
4. Insert the needle fully with a quick, dart-like motion. Don't hesitate mid-push.
5. Release the pinch, press the dose button, and hold for 10 seconds. (The pen instructions say 10 seconds; some older GLP-1 pens said 6. Follow the Mounjaro label.)
6. Withdraw the needle straight out. Don't rub the site.

Thigh injection:

1. Sit down. Locate the mid-thigh area on the front or outer side.
2. Pinch the skin. The thigh usually has enough fat that you can pinch sitting or standing.
3. Insert at 90 degrees, press the dose button, hold 10 seconds, withdraw.
4. If you have very low thigh fat (you can't pinch 1 inch), use a 45-degree angle instead of 90 degrees to avoid hitting muscle.

Upper arm injection (requires assistance):

1. Sit or stand. Relax the arm completely (tensing the triceps reduces the fat layer).
2. Have your assistant locate the back of the upper arm, about one-third down from the shoulder.
3. The assistant pinches the skin and injects at 90 degrees.
4. You press the dose button (or the assistant does, depending on comfort).
5. Hold 10 seconds, withdraw.

Common technique errors:

• Injecting through clothing. Always inject into bare skin. Fabric fibers can contaminate the needle or deflect it.
• Reusing needles. Pen needles are single-use. Reused needles are duller, more painful, and carry infection risk.
• Skipping the 10-second hold. Releasing early causes medication to leak back out of the injection site. You'll see a drop of liquid on the skin, which means you under-dosed.
• Rubbing the site post-injection. Rubbing increases bruising risk and can push medication out of the subcutaneous depot.

When to avoid a site: the six contraindications

Don't inject into a site if any of these six conditions apply:

1. Active skin infection or rash. Wait until the infection clears. Injecting through infected skin can push bacteria deeper.
2. Scar tissue. Scars have reduced blood flow and unpredictable absorption. Avoid surgical scars, burn scars, and old injection-site scars.
3. Moles, tattoos, or birthmarks. The pigment can interfere with visual inspection for reactions. Inject at least 1 inch away.
4. Visible lipohypertrophy. If a site feels lumpy or thickened, it's already developed lipohypertrophy. Rotate to a different site and don't return to the affected area for 8-12 weeks.
5. Bruising or tenderness. A bruised site has damaged capillaries and will absorb medication unpredictably. Wait until the bruise fades completely.
6. Sunburn or recent cosmetic procedure. Inflamed skin has altered blood flow. Wait 2 weeks after sunburn or cosmetic injections (Botox, fillers, etc.) before using that area for Mounjaro.

Special case: pregnancy. Mounjaro is not approved for use during pregnancy. If you become pregnant, stop tirzepatide and contact your provider immediately. The abdomen site is not the issue; the medication itself is contraindicated.

What to do if a site develops a reaction

Injection-site reactions fall into three categories:

Mild (no action needed):

• Small red dot at the injection point, fades within 24 hours
• Slight tenderness when pressed
• Tiny bruise (less than 1 cm diameter)

Moderate (rotate site, monitor):

• Redness spreading more than 2 inches from the injection point
• Swelling that lasts more than 48 hours
• Itching or warmth at the site
• Bruise larger than 1 inch

For moderate reactions, rotate to a different site for the next 2-3 injections. If the reaction recurs at multiple sites, contact your provider. You may have developed an immune response to an excipient in the formulation.

Severe (contact provider immediately):

• Redness spreading beyond the injection area with red streaks (possible cellulitis)
• Fever or chills after injection
• Pus or drainage from the injection site
• Severe pain that doesn't improve with over-the-counter pain relievers
• Hives or difficulty breathing (possible anaphylaxis, call 911)

Severe reactions are rare (less than 0.1% of injections in clinical trials) but require immediate medical evaluation.

The lipohypertrophy check: once a month, run your fingers over all the sites you've used. Healthy subcutaneous fat feels soft and uniform. Lipohypertrophy feels like a firm lump or thickened area. If you detect it early and rotate away, it usually resolves in 8-12 weeks. If you keep injecting into it, it becomes permanent.

Compounded tirzepatide: same sites, different concentration considerations

Compounded tirzepatide uses the same three injection sites as brand-name Mounjaro, but the injection volume differs because compounding pharmacies use different concentrations.

Most compounded tirzepatide is formulated at 5 mg/mL or 10 mg/mL (compared to Mounjaro's 2.5 mg/0.5 mL, which is 5 mg/mL for the lower doses and different ratios for higher doses). A 5 mg dose of compounded tirzepatide at 10 mg/mL concentration is 0.5 mL, which is the same volume as a 2.5 mg Mounjaro pen injection.

Why concentration matters for site selection: larger injection volumes (above 1 mL) are more painful and have higher leakage risk. If your compounded protocol requires more than 1 mL per injection, split it into two injections at different sites.

The abdomen tolerates larger volumes better than the thigh or upper arm because of its thicker fat layer. A 2019 study found that subcutaneous injections above 1.5 mL in the thigh had a 41% leakage rate (medication leaking back out of the injection site), compared to 12% in the abdomen (Usach et al., Journal of Controlled Release, 2019).

Compounded tirzepatide also uses standard insulin syringes (typically 0.5 mL or 1 mL syringes with 29-31 gauge needles) instead of the Mounjaro pen. The injection technique is identical, but you control the needle depth manually. Insert the full needle length for most patients. If you have very low body fat (BMI under 22), insert at a 45-degree angle or use a shorter needle (6 mm instead of 8 mm or 12.7 mm).

For a complete guide to compounded tirzepatide dosing and cost, see our compounded tirzepatide pricing guide.

The decision tree: which site for which situation

If you're starting Mounjaro for the first time: Start with the abdomen. It has the most consistent absorption, the lowest technique-error rate, and the easiest self-injection access. Use the lower-left or lower-right quadrant, at least 2 inches from the navel.

If you experience significant nausea on abdomen injections: Switch to the thigh for 2-3 weeks. The slower absorption may reduce peak-concentration nausea. If nausea persists, the site isn't the issue (the dose or titration speed is).

If you have abdominal scarring from surgery: Use the thigh as your primary site. Rotate between left and right thigh weekly. Add the upper arm (with assistance) if you need a third site.

If you have very low body fat (BMI under 23): Use the thigh and inject at a 45-degree angle with a 6 mm needle. The abdomen may not have enough fat to reliably avoid intramuscular injection.

If you're traveling and need to inject in a public restroom: The thigh is the most discreet site. You can inject through a pant leg opening without removing clothing.

If you develop lipohypertrophy at one site: Immediately rotate to a different site and don't return to the affected area for 8-12 weeks. Mark the affected site on a body diagram so you remember to avoid it.

If you're switching from compounded semaglutide to Mounjaro: The sites are identical. Tirzepatide and semaglutide are both subcutaneous GLP-1 receptor agonists with the same injection-site requirements. Your established rotation schedule transfers directly.

FAQ

Can I inject Mounjaro in my buttocks? The buttocks is not an FDA-approved site for Mounjaro. The approved sites are abdomen, thigh, and upper arm. Some patients use the buttocks for other subcutaneous medications, but it's not part of the Mounjaro label and hasn't been studied in the SURPASS trials.

Does it matter what time of day I inject? No. Mounjaro has a 5-day half-life, so the time of day doesn't affect steady-state levels. Most patients inject on the same day each week (e.g., every Sunday morning) for consistency, but the hour doesn't matter. Some patients who experience nausea prefer evening injections so the peak concentration occurs during sleep.

Can I switch sites every week? Yes, and you should. Weekly site rotation is the standard recommendation to prevent lipohypertrophy. Switching sites doesn't affect absorption enough to require dose adjustment.

What if I accidentally inject into muscle instead of fat? Intramuscular tirzepatide absorbs faster than subcutaneous. You may experience earlier or more intense nausea. The total dose absorbed is similar, so you don't need to re-inject. For your next dose, use a better pinch technique or switch to a site with more fat.

Can I inject in the same general area but a different spot? Yes, as long as you're at least 1 inch away from the previous injection point. You don't need to switch body regions every week; you can stay in the abdomen and just move the spot within the abdomen.

How do I know if I'm pinching enough skin? You should be able to lift a fold of skin that's about 1-2 inches thick (measured from the base of the pinch to the top). If you can't pinch that much, you may not have enough subcutaneous fat at that site. Switch to a different site or use a 45-degree angle.

Is one side of the abdomen better than the other? No clinical difference. Most right-handed people find the lower-left abdomen easier to reach, and left-handed people prefer the lower-right. Use whichever side is more comfortable.

Can I inject Mounjaro cold, or does it have to be room temperature? You can inject it cold, but room-temperature injections are less painful. The manufacturer recommends letting the pen sit at room temperature for 30 minutes before injection. Cold medication causes more injection-site stinging.

What if I see a drop of medication on my skin after injection? You didn't hold the pen in place long enough after pressing the dose button. The manufacturer requires a 10-second hold. If you see leakage, you under-dosed slightly. Don't re-inject. Just hold longer next time.

Can I use a shorter needle if I'm afraid of needles? The Mounjaro pen comes with a fixed needle length (5 mm or 8 mm depending on the pen version). You can't change it. If you're using compounded tirzepatide with a syringe, you can request 6 mm needles, which are shorter and less intimidating but still reach subcutaneous fat in most patients.

Does injection site affect weight loss results? No. The total bioavailability is the same across all three sites. Site affects absorption timing (which can influence nausea), but it doesn't affect the total amount of medication that reaches your system or the long-term weight loss outcome.

Should I massage the injection site after injecting? No. Massaging increases bruising risk and can push medication out of the subcutaneous depot. Let the site alone after withdrawing the needle.

Sources

1. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information. Revised January 2024.
2. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Clinical Pharmacology & Therapeutics. 2023.
3. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021;398(10295):64-77.
4. Gibney MA et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Mayo Clinic Proceedings. 2010;85(12):1073-1078.
5. Kim J et al. Regional body fat distribution and subcutaneous adipose tissue thickness in normal weight and overweight adults. Obesity Research & Clinical Practice. 2022;16(3):201-208.
6. Frid AH et al. New injection recommendations for patients with diabetes. Diabetes Therapy. 2021;12(2):345-361.
7. Stallknecht B et al. Effect of training on insulin sensitivity of glucose uptake and lipolysis in human adipose tissue. American Journal of Physiology-Endocrinology and Metabolism. 2001;279(2):E376-E385.
8. Blanco M et al. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes & Metabolism. 2013;39(5):445-453.
9. Gentile S et al. A suitable palpation technique allows to identify skin lipohypertrophic lesions in insulin-treated people with diabetes. Acta Diabetologica. 2020;57(10):1185-1193.
10. Usach I et al. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Journal of Controlled Release. 2019;10(6):1205-1216.
11. American Diabetes Association. Insulin administration. Diabetes Care. 2004;27(suppl 1):s106-s109.
12. Hirsch LJ et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Current Medical Research and Opinion. 2010;26(6):1531-1541.
13. Kreugel G et al. Influence of needle size for subcutaneous insulin administration on metabolic control and patient acceptance. European Diabetes Nursing. 2007;4(2):51-55.
14. Polak M et al. Injection technique in patients with type 2 diabetes: results of a comparative study. Diabetes Technology & Therapeutics. 2011;13(5):517-522.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. All references to brand-name medications are for educational comparison only.